Felipe Couñago, National Clinical Director of GenesisCare Spain, shared on LinkedIn:
“Now Published in ctRO – Clinical and Translational Radiation Oncology!
I am delighted to share that our prospective study,
‘MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes‘
is now officially published and available as Open Access.
Title: MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes
Authors: Daniela Gonsalves Pieretti, Fernando López-Campos, Abrahams Ocanto, Maria González, Lisselott Torres, Castalia Fernandez, Gloria Sanchez, Gloria Guardia, Alvaro Flores, Jon Andreescu, Laura Viduera, Dulce Urias, Ofelia Cabanes, Julia Rogriguez, Sigfredo Elias Romero Zoghbi, Jose Antonio González, Miren Gaztañaga, Luis Glaria, Maia Dzhugashvili, Stefano Arcangeli, Federica Ferrari, Juan Ignacio Martinez Salamanca, Giulio Francolini, Felipe Couñago.
Read The Full Article.
In this prospective study of 31 consecutive patients treated with online adaptive MR-guided SBRT to the prostate bed after radical prostatectomy, we observed:
- No grade ≥3 treatment-related adverse events.
- Only 4.3% grade ≥2 genitourinary adverse events at 6 months.
- 0% grade ≥2 gastrointestinal adverse events.
- Preservation of urinary and bowel quality of life throughout follow-up.
- 100% biochemical response during the early follow-up period.
To our knowledge, this is the first prospective Spanish study reporting clinical outcomes and patient-reported quality-of-life data for online adaptive MR-guided SBRT in the post-prostatectomy setting.
Congratulations to Dr. Daniela Gonsalves Pieretti for leading this outstanding work. I would also like to thank all co-authors, collaborators and, most importantly, our patients and their families for making this research possible.
This publication represents another important milestone for our MR-Linac clinical research program, with a second prospective ctRO study on localized prostate cancer expected to be published soon.”